Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

Shares of Viking Therapeutics are trading within a consolidated range as the market anticipates significant corporate news. The biotechnology firm is scheduled to release its financial results for the fourth quarter and full year 2025 after the market closes on February 11, 2026. The primary focus for the investment community will be on progress within the company’s clinical development pipeline.

Clinical Pipeline Commands Attention

The upcoming earnings call, featuring management commentary, is expected to provide more than just financial metrics. General business updates will be presented, with investor attention firmly fixed on two late-stage trials.

Advancements in the Phase 3 VANQUISH-1 and VANQUISH-2 studies are of particular interest. These trials are evaluating the subcutaneous formulation of the drug candidate VK2735 for the treatment of obesity. Market participants will also be listening for any developments regarding the oral version of VK2735, as well as updates on VK2809, which is being developed for non-alcoholic steatohepatitis (NASH).

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Recent Operational Milestones

The company has recently announced several developments. In early January, Viking Therapeutics disclosed the publication of its Phase 2 VENTURE study results for VK2735 in a peer-reviewed medical journal. Later that same month, the company confirmed it had completed patient enrollment for a clinical trial investigating a maintenance dosing regimen for VK2735.

Viking operates in the highly competitive and closely watched markets for obesity and NASH therapeutics, where novel treatment approaches generate significant interest. The forthcoming annual report will offer a fresh look at how these clinical programs have progressed. The conference call on February 11 may deliver concrete insights into the next anticipated milestones for these studies.